177 related articles for article (PubMed ID: 19158050)
21. Oncogenic osteomalacia, a rare paraneoplastic syndrome due to phosphate wasting--a case report and review of the literature.
Woznowski M; Quack I; Stegbauer J; Büchner N; Rump LC; Schieren G
Clin Nephrol; 2008 Nov; 70(5):431-8. PubMed ID: 19000546
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast Growth Factor-23 and Matrix Extracellular Phosphoglycoprotein Levels in Healthy Children and, Pregnant and Puerperal Women.
Ozsen A; Furman A; Guran T; Bereket A; Turan S
Horm Res Paediatr; 2019; 92(5):302-310. PubMed ID: 32187608
[TBL] [Abstract][Full Text] [Related]
23. Evidence of downregulation of matrix extracellular phosphoglycoprotein during terminal differentiation in human osteoblasts.
Siggelkow H; Schmidt E; Hennies B; Hüfner M
Bone; 2004 Aug; 35(2):570-6. PubMed ID: 15268910
[TBL] [Abstract][Full Text] [Related]
24. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia.
Kumar R
Curr Opin Nephrol Hypertens; 2002 Sep; 11(5):547-53. PubMed ID: 12187320
[TBL] [Abstract][Full Text] [Related]
25. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone.
Nampei A; Hashimoto J; Hayashida K; Tsuboi H; Shi K; Tsuji I; Miyashita H; Yamada T; Matsukawa N; Matsumoto M; Morimoto S; Ogihara T; Ochi T; Yoshikawa H
J Bone Miner Metab; 2004; 22(3):176-84. PubMed ID: 15108058
[TBL] [Abstract][Full Text] [Related]
26. Effects of tumor-induced osteomalacia on the bone mineralization process.
Nawrot-Wawrzyniak K; Varga F; Nader A; Roschger P; Sieghart S; Zwettler E; Roetzer KM; Lang S; Weinkamer R; Klaushofer K; Fratzl-Zelman N
Calcif Tissue Int; 2009 Apr; 84(4):313-23. PubMed ID: 19219382
[TBL] [Abstract][Full Text] [Related]
27. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia.
Liu S; Brown TA; Zhou J; Xiao ZS; Awad H; Guilak F; Quarles LD
J Am Soc Nephrol; 2005 Jun; 16(6):1645-53. PubMed ID: 15843468
[TBL] [Abstract][Full Text] [Related]
28. FGF-23 in bone biology.
Wesseling-Perry K
Pediatr Nephrol; 2010 Apr; 25(4):603-8. PubMed ID: 20012997
[TBL] [Abstract][Full Text] [Related]
29. [Establishment of assay system for fibroblast growth factor (FGF)-23 and pathophysiological roles of FGF-23 in the development of hypophosphatemic diseases].
Fukumoto S; Nakahara K
Rinsho Byori; 2004 Jan; 52(1):51-4. PubMed ID: 14968560
[TBL] [Abstract][Full Text] [Related]
30. Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia.
Nelson AE; Bligh RC; Mirams M; Gill A; Au A; Clarkson A; Jüppner H; Ruff S; Stalley P; Scolyer RA; Robinson BG; Mason RS; Bligh PC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4088-94. PubMed ID: 12970268
[TBL] [Abstract][Full Text] [Related]
31. [Phosphatonins: novel insights and clinical perspectives].
Mossetti G; Rendina D; De Filippo G; Zampa G; Strazzullo P
G Ital Nefrol; 2009; 26(2):171-80. PubMed ID: 19382073
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
[TBL] [Abstract][Full Text] [Related]
33. Persistent tumor-induced osteomalacia confirmed by elevated postoperative levels of serum fibroblast growth factor-23 and 5-year follow-up of bone density changes.
Zimering MB; Caldarella FA; White KE; Econs MJ
Endocr Pract; 2005; 11(2):108-14. PubMed ID: 15901526
[TBL] [Abstract][Full Text] [Related]
34. Intracranial phosphaturic mesenchymal tumors: report of 2 cases.
Mathis DA; Stehel EJ; Beshay JE; Mickey BE; Folpe AL; Raisanen J
J Neurosurg; 2013 Apr; 118(4):903-7. PubMed ID: 23350780
[TBL] [Abstract][Full Text] [Related]
35. A case report of tumor-induced osteomalacia: eight year followed-up.
Ratanasuwan T; Chetsurakarn S; Ongphiphadhanakul B; Damrongkitchaiporn S
J Med Assoc Thai; 2008 Dec; 91(12):1900-2. PubMed ID: 19133527
[TBL] [Abstract][Full Text] [Related]
36. Renal Phosphate Wasting Due to Tumor-Induced (Oncogenic) Osteomalacia.
Amaratunga EA; Ernst EB; Kamau J; Kotala R; Snyder R
Cureus; 2021 Jun; 13(6):e15507. PubMed ID: 34268038
[TBL] [Abstract][Full Text] [Related]
37. [Oncogenic osteomalacia: the role of the phosphatonins. Diagnostic usefulness of the Fibroblast Growth Factor 23 measurement in one patient].
Dupond JL; Magy N; Mahammedi M; Prie D; Gil H; Meaux-Ruault N; Kantelip B
Rev Med Interne; 2005 Mar; 26(3):238-41. PubMed ID: 15777586
[TBL] [Abstract][Full Text] [Related]
38. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia.
Takeuchi Y; Suzuki H; Ogura S; Imai R; Yamazaki Y; Yamashita T; Miyamoto Y; Okazaki H; Nakamura K; Nakahara K; Fukumoto S; Fujita T
J Clin Endocrinol Metab; 2004 Aug; 89(8):3979-82. PubMed ID: 15292336
[TBL] [Abstract][Full Text] [Related]
39. Mutational landscape and genetic signatures of cell-free DNA in tumour-induced osteomalacia.
Wu N; Zhang Z; Zhou X; Zhao H; Ming Y; Wu X; Zhang X; Yang XZ; Zhou M; Bao H; Chen W; Wu Y; Liu S; Wang H; Niu Y; Li Y; Zheng Y; Shao Y; Gao N; Yang Y; Liu Y; Li W; Liu J; Zhang N; Yang X; Xu Y; Li M; Sun Y; Su J; Zhang J; Xia W; Qiu G; Liu Y; Liu J; Wu Z
J Cell Mol Med; 2020 May; 24(9):4931-4943. PubMed ID: 32277576
[TBL] [Abstract][Full Text] [Related]
40. [Expression of matrix extracellular phosphoglycoprotein mRNA in human periodontal ligament cell osteogenic differentiation].
Wu LP; Wei X; Ling JQ; Liu L
Zhonghua Kou Qiang Yi Xue Za Zhi; 2008 Jun; 43(6):362-6. PubMed ID: 19031789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
